Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 1999

View Archived Issues

Genzyme General: Q1 1999 highlights

Novel pressure-mediated drug delivery technology available for licensing from NIH

Copernicus obtains broad patent protection for nucleic acid delivery technology

Spotlight on treatment of attention deficit hyperactivity disorder

Celebrex launched in Canada for arthritis

Vitravene recommended for European approval as CMV retinitis therapy

Schering-Plough: Annual Report 1998

Ethyol granted E.U. approval for use in radiation therapy

Amylin's pramlintide given trademark

Mallinckrodt takes over Optison manufacturing

DuPont presents new series of HIV reverse transcriptase inhibitors

Protease inhibitors in development at SmithKline Beecham

Urea-based compounds from AHP increase HDL cholesterol levels

Inhibitors of 5alpha-reductase claimed by L'Oreal for androgen-dependent skin disorders

New oxazolidinones claimed by Zeneca (AstraZeneca)

Merck researchers prepare potential antipsychotic compounds with reduced side effects

NG-061: a novel fungal metabolite with neurotrophic effects in PC12 cells

Potent and selective small-molecule thrombin inhibitor developed at DuPont

PDL issued U.S. patent covering its SMART anti-CD3 antibody

Patent provides Cortex exclusive use of AMPA receptor modulators for improving memory, cognition

GeneSwitch technology patent coverage expanded

Mammastatin cleared for clinical trials in late-stage breast cancer

Iomai demonstrates feasibility and safety of transcutaneous immunization

NDA filed for first oral neuraminidase inhibitor for the flu

Company Profile: Vaxis Therapeutics

SK-951 identified as a potent 5-HT4 agonist/5-HT3 antagonist

Phase I pharmacokinetic, safety and efficacy results reported for KNI-272

Company Profile: Genetix